Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia. (2021)

Peer-Reviewed Study · Fabian Freisleben; Franziska Modemann; Jana Muschhammer et al. · October 1, 2021

Fabian Freisleben et al., 2021-10-01: AML study showing mebendazole lowers GLI1/GLI2 and Hedgehog reporter activity by driving proteasomal degradation through HSP70/90 inhibition, with two off-label patient treatments described.

Further analysis revealed that MBZ mediates its anti-leukemic effects by promoting the proteasomal degradation of GLI transcription factors via inhibition of HSP70/90 chaperone activity.

Fabian Freisleben et al., 2021-10-01: AML study showing mebendazole lowers GLI1/GLI2 and Hedgehog reporter activity by driving proteasomal degradation through HSP70/90 inhibition, with two off-label patient treatments described. Study type: AML cell lines plus two off-label patient treatments (N=2). Country: Germany (University Medical Center Hamburg-Eppendorf). Dose: not stated in the abstract text captured. Funder: Erich und Gertrud Roggenbuck-Stiftung; German Federal Ministry of Education and Research (13FH156IN6). Declared conflicts: F.M. reports meeting support from Servier, Incyte, Gilead, Jazz, Novartis, Teva, Pfizer and Amgen, a research grant from Daiichi Sankyo and speaker honoraria. Comparator: cytarabine, in combination.